Clinical Trials Logo

Clinical Trial Summary

A single arm observational study investigating the incidence of brain metastasis in patients with cancer recti and lung metastasis


Clinical Trial Description

In this study the investigators want to investigate the incidence of brain metastasis in a selected high-risk group of patients with metastatic colorectal cancer. Possible prognostic biological aspects will be investigated by translational analysis of biological samples. The study population consists of patients with metastatic rectal cancer and presence of lung metastasis. The patients will undergo a standard MRI scan of the brain including injection of intravenous contrast. If positive finding, images will be evaluated at the multidisciplinary tumor board for potential treatment options according to clinical practice. Standard follow-up program is followed, as per clinical practice. If the initial MRI scan of cerebrum detects brain metastasis this will be treated and followed as per clinical practice. Translational blood samples will be drawn at inclusion and at every imaging schedule up til 5 times ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05185557
Study type Observational
Source Aarhus University Hospital
Contact Louise B Callesen, MD
Phone 30482884
Email [email protected]
Status Recruiting
Phase
Start date August 16, 2021
Completion date February 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04474925 - Pre- Versus Post-operative SRS for Resectable Brain Metastases Phase 3
Completed NCT02082587 - Toronto BNB Pilot Study N/A
Terminated NCT01551680 - A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases Phase 1
Terminated NCT00717275 - Study of Temozolomide to Treat Newly Diagnosed Brain Metastases Phase 2
Recruiting NCT03714243 - Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases N/A
Recruiting NCT04899908 - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases Phase 2
Recruiting NCT04170777 - Perfexion Registration Using CBCT
Not yet recruiting NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Recruiting NCT04582968 - Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases Phase 1/Phase 2
Recruiting NCT03027544 - Tomotherapy for Refractory Brain Metastases N/A
Completed NCT04178330 - Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases N/A
Terminated NCT02187822 - Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Phase 1
Recruiting NCT04246879 - MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases N/A
Active, not recruiting NCT03653546 - First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases Phase 2/Phase 3
Recruiting NCT04410133 - Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases Phase 3
Recruiting NCT04040400 - Study of Intraoperative Radiotherapy for Patients With Large Brain Metastases Treated With Neurosurgical Resection N/A
Recruiting NCT04115254 - Stereotactic Magnetic Resonance Guided Radiation Therapy N/A
Recruiting NCT04824079 - Keynatinib in Treated Patients With NSCLC and Brain Metastases Phase 2
Recruiting NCT02886585 - Pembrolizumab In Central Nervous System Metastases Phase 2
Completed NCT01480583 - GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases Phase 2